In a groundbreaking development, human-derived fat, previously discarded as medical waste during liposuction and cosmetic surgeries, is now poised to become a valuable resource for regenerative medicine and the biotech industry. This shift marks a significant transformation for human fat, which was once entirely incinerated, into a high-value biomaterial.
On Monday, the National Assembly passed an amendment to the Waste Management Act, removing human-derived fat from the list of medical waste prohibited from recycling.
Current law classifies human tissue extracts as medical waste, generally barring their reuse. The placenta stands as a rare exception, allowed for use in pharmaceutical production under specific regulations. This new amendment establishes a legal framework for recycling human-derived fat, subject to criteria and procedures set by presidential decree.
Industry experts estimate that liposuction procedures in South Korea generate about 30 tons of human-derived fat annually. Previously incinerated in its entirety, this fat can now be repurposed as a bio-raw material under the new legislation.
Human-derived fat is prized for its rich content, including not just fat cells but also adipose-derived stem cells, collagen, and extracellular matrix (ECM). The biotech sector is particularly excited about ECM’s potential. As a substance that supports cellular structure, ECM could be pivotal in developing various biomedical products, from wound dressings and burn treatments to cell culture media and dermal fillers.
Kim Nam-cheol, Chief Executive Officer (CEO) of 365mc, believes this legal change will spotlight the value of human fat, potentially boosting the adipose stem cell market. However, he predicts that the diverse applications of biomaterials like ECM will have an even greater impact on biotech industry growth than stem cells alone.
365mc, a leader in liposuction procedures, had been conducting research in this area even before the law changed. The company collaborated with the Daegu-Gyeongbuk Medical Complex to validate the use of human-derived fat and established a subsidiary, Monicell, focused on adipose-derived stem cell and ECM research. Kim stated that with full-scale industrialization now possible, it’s ramping up the research into new biomaterials and cosmetic ingredients.
Lee Seung-kyu, vice president of the Korea Bio Association, emphasized the importance of human-derived materials in developing diagnostic kits, regenerative therapies, and biomaterials. He highlighted fat’s particular value due to its diverse cellular and molecular content. Lee anticipates that bringing previously informal practices into a regulated framework will significantly energize related industries.
As regulations are implemented, the industry expects key issues to include safety standards for fat collection, storage, transport, and processing, as well as patient consent procedures and traceability systems.
Kim expressed confidence that regulatory authorities will establish effective safety protocols, citing South Korea’s experience with cell therapies and placental materials.
Lee stressed the need for balanced regulation, advocating for safety measures to prevent misuse while cautioning against excessive red tape that could stifle innovation. He emphasized the importance of striking a balance between safety concerns and industry growth as new guidelines are developed.
